IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 14/10/2020 - Press release

    Dr. Scott Boyer joins Chemotargets as new CEO

    Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, has appointed Dr. Scott Boyer as new CEO with the aim to consolidate its transition from a software business to a key player in the biotech sector. Dr Boyer joins Chemotargets from Swedish drug development company Klaria, where he has been CEO/CSO since 2015 and will continue as a member of the Board of Directors and as a scientific advisor. Prior to joining Klaria, he was Chief Scientist at AstraZeneca (Sweden), with global responsibility for molecular and investigational toxicology across the company, and a member of the company's senior management team.  Prior to AstraZeneca, Dr. Boyer was a senior scientist at Pfizer Central Research in the US.

    Més informació "Dr. Scott Boyer joins Chemotargets as new CEO"

  • 15/09/2020 - Press release

    Decryption of a molecular code that regulates the behavior of the cells

    The research group of GPCR Drug Discovery at the Hospital del Mar Medical Research Institute (IMIM), in collaboration with the Indian Institute of Technology in Kanpur, has deciphered how nature adjusts the response of the human cell to abundant extracellular stimuli (e.g., smell, taste, light, hormones, etc.). When a cell receives an extracellular stimulus, it initiates a signaling process that can result in major physiological changes. This process is mediated by cell membrane proteins such as G protein coupled receptors (GPCRs). Depending on the stimulus, those receptors regulate cell activity through different molecular mechanisms.  Extracellular stimulation of GPCRs leads to its activation and subsequently to the phosphorylation of its long intracellular tail. Interestingly, there are multiple phosphorylation patterns of the receptor tail - each of them linked to a specific signaling response. The phosphorylation code is read by intracellular proteins known as β-arrestins. In response, they typically silence the receptor and modulate intracellular kinases, which have a global impact on cell behaviour related to gene expression, cell survival and cell death. "Until now, the phosphorylation code and the involvement of arrestins in deciphering it has been an open question" explains Dr. Selent. "We have discovered the underlying molecular mechanism of how arrestin reads and translates a specific phosphorylation pattern into a cellular response" she adds.

    Més informació "Decryption of a molecular code that regulates the behavior of the cells"

  • 14/07/2020 - Press release

    New tool for studying a key drug target

    G protein-coupled receptors (GPCRS) are one of the key elements mediating basic stimuli like our response to mosquito bites or to this last-minute goal scored by our favorite football team. In fact, these proteins are the target of almost 40% of the currently approved drugs. However, until now, researchers did not have access to a tool employing molecular simulations to achieve a better understanding of GPCR function. Therefore, a consortium of researchers from 23 different institutions of 10 different European countries and the United States have joined forces to design and build a tool that will help improve our understanding of the function of these receptors, which are responsible of transmitting signals to the interior of cells. The GPCRmd platform is the result of this work, lead and coordinated by the GPCR Drug Discovery group from the Research Programme on Biomedical Informatics (GRIB) of the Hospital del Mar Medical Research Institute (IMIM), the Pompeu Fabra University, and the Paul Scherrer Institute (PSI) in Switzerland, with support from the Autonomous University of Barcelona.

    Més informació "New tool for studying a key drug target"

  • 25/05/2020 - Press release

    Alliance between the Hospital del Mar Medical Research Institute and Chemotargets to accelerate the design of new cancer therapies

    The company Chemotargets -based in the Barcelona Science Park and a global leader in the development of computational platforms for the design, optimization and safety evaluation of drugs- has signed a strategic agreement with the Hospital del Mar Medical Research Institute (IMIM) in order to accelerate research projects for the discovery and development of new oncological therapies that respond to important unmet medical needs. This public-private partnership will establish a framework for collaboration that promotes the creation of synergies between the IMIM experience in the identification of new therapeutic targets in emerging fields of cancer biology and the Chemotargets expertise in drug discovery and development. This initiative will include the use of cutting-edge computational technologies developed specifically to rapidly design drug candidates acting on new mechanisms of action or directed to targets that are difficult to address and for which no identified drugs currently exist.

    Més informació "Alliance between the Hospital del Mar Medical Research Institute and Chemotargets to accelerate the design of new cancer therapies"

  • 06/05/2020 - Press release

    The FDA licenses Chemotargets CLARITY platform

    The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has licensed the Chemotargets CLARITY® platform for predicting unknown secondary targets for new molecules of pharmaceutical interest. This contract is meant to directly address the FDA's requirement for a computational method which can predict potential molecular targets from chemical structure and provide a user-friendly environment for analysis of results. Molecular targets identified with high confidence by CLARITY® may be evaluated by FDA/CDER for their association with adverse events, addiction liability, or their association with disease within the specified indication(s).

    Més informació "The FDA licenses Chemotargets CLARITY platform"

  • 17/04/2020 - Press release

    Chemotargets opens an investment round to enter a new phase of growth

    Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, begins a phase of transformation to become a biotechnology company that will develop new medicines in multiple therapeutic areas, with an initial focus on oncology. Founded in 2006 as a spin-off from Dr. Jordi Mestres' Systems Pharmacology lab under the auspices of the IMIM Hospital del Mar Medical Research Institute, a leading academic centre of excellence based in Barcelona, Chemotargets is opening an investment round to undertake the transformation of its business model. Genesis Biomed, a well-established consultancy firm in the health and biotech sectors, and CREA Inversión, an M&A boutique advisory firm specialised in corporate transactions and financing, will advise Chemotargets in this transformation.

    Més informació "Chemotargets opens an investment round to enter a new phase of growth"

  • 06/02/2020 - Press release

    The spin-off MedBioinformatics Solutions is born to offer software and consultancy on relationships between genes and diseases

    Ten years ago, researchers at Hospital del Mar Medical Research Institute (IMIM) and at Pompeu Fabra University (UPF) created a computer platform for collecting highly relevant scientific information that had, until then, been scattered across several sources: relationships between genes and diseases. This open access tool called DisGeNET has become a benchmark in the field of research. From now on, it will also have an industrial application thanks to MedBioinformatics Solutions, a spin-off of IMIM and UPF that is to develop software and consulting services that will bring added value to the information of DisGeNET to help companies develop new products and services. The company came to life today, 6 February, with the signing of the deeds of incorporation by the acting director of IMIM, Jorge Martínez, the UPF general manager, Jaume Badia; the researchers and partners of the company, Ferran Sanz, Laura Furlong, Janet Piñero and Olga Valverde, and the investor partners: Frederic Abelló and the companies Prous Institute for Biomedical Research and Icrowd+D.

    Més informació "The spin-off MedBioinformatics Solutions is born to offer software and consultancy on relationships between genes and diseases"

  • 27/11/2019 - Press release

    Women researchers and directives explain the latest advances in artificial intelligence, big data and other technologies used in biomedical research (Press release sent byBSC)

    Outstanding women researchers who use the latest computer advances for biomedical research and directives from companies and institutions in the world of technology and biomedicine will present the latest developments in this field of research and discuss the most immediate challenges at the end of November in Barcelona. The meeting will take place during the first edition of the Advances in Computational Biology (AdvCompBio) conference, which will gather around 200 attendees in the auditorium of La Pedrera in Barcelona on November 28 and 29. In this conference, all speakers and organizers are women, although the sessions will be open to everyone. AdvCompBio is primarily a high-level international scientific meeting, intended to discuss the latest artificial intelligence and big data technologies in computational biology, promote the exchange of experiences and create collaborative networks.

    Més informació "Women researchers and directives explain the latest advances in artificial intelligence, big data and other technologies used in biomedical research (Press release sent byBSC)"

  • 08/10/2019 - Press release

    Our own bodies hold the key to designing safer drugs

    Based on a study of 566 drugs that interact with 129 different proteins, researchers from the Systems Pharmacology research group, part of the GRIB Research Programme on Biomedical Informatics, a joint programme between the Hospital del Mar Medical Research Institute (IMIM) and Pompeu Fabra University (UPF), in collaboration with researchers from the University of New Mexico, in the United States, realised that 71% of drugs have stronger affinities for their target proteins than those of the small internal molecules responsible for regulating their functions. Surprisingly, this is the first time that the affinities of endogenous ligands and drugs for the same proteins have been quantified. Humans have thousands of proteins, each with a specific function that is often regulated by thousands of small molecules synthesised by our bodies. This set of small molecules, also known as "endogenous metabolites", is known as the "human metabolome". Each one interacts with its native protein with a certain affinity that has been carefully optimised, in a natural way, throughout the long process of evolution, and this can vary between species and even in some instances, more subtly, between individuals.

    Més informació "Our own bodies hold the key to designing safer drugs"

  • 11/07/2018 - Press release

    A new computational method for exploring the reuse of drugs

    Researchers led by Emre Guney of the research programme on Biomedical Informatics (GRIB), a joint programme of Pompeu Fabra University (UPF) and the Hospital del Mar Medical Research Institute (IMIM), have developed a new computational method to reuse drugs that target biological pathways common to more than one disease. A significant percentage of marketed drugs are not effective in patients due to the complexity of the biological processes involved in diseases and genetic differences between people. Despite recent technological advances, the discovery of new effective treatments takes a long time and continues to be expensive. For this reason, the reuse of medicines, i.e., the use of existing drugs for other diseases, is a very interesting alternative to reduce the costs of drug development.

    Més informació "A new computational method for exploring the reuse of drugs"

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact